Pain · Tulsa, OK
Pain studies in Tulsa, OK
7 recruiting studies have a site in Tulsa.
7 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
An Open-Label, Safety and Efficacy Study of Cebranopadol in Participants With Acute Pain With Surgical or Non-Surgical Origin
Adneuris Therapeutics, Inc.
- Location
- Tulsa, OK + 14 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
Eli Lilly and Company
- Location
- Tulsa, OK + 37 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain
Eli Lilly and Company
- Location
- Tulsa, OK + 34 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design
Axsome Therapeutics, Inc.
- Location
- Tulsa, OK + 48 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Chronic Low Back Pain
Eli Lilly and Company
- Location
- Tulsa, OK + 31 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis Pain
Eli Lilly and Company
- Location
- Tulsa, OK + 35 other US sites
- Eligibility basics
- Ages 40+
- RecruitingPhase 2
A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain
Eli Lilly and Company
- Location
- Tulsa, OK + 35 other US sites
- Eligibility basics
- Ages 18+
Who these studies look for
Studies usually set a pain score range and limits on pain medicines. Some short-term pain studies involve a scheduled minor procedure.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.